X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs CADILA HEALTHCARE - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. CADILA HEALTHCARE FRESENIUS KABI ONCO./
CADILA HEALTHCARE
 
P/E (TTM) x 22.1 18.4 120.5% View Chart
P/BV x 3.1 4.2 74.8% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 FRESENIUS KABI ONCO.   CADILA HEALTHCARE
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
CADILA HEALTHCARE
Mar-18
FRESENIUS KABI ONCO./
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs176558 31.5%   
Low Rs79362 21.7%   
Sales per share (Unadj.) Rs37.7116.3 32.4%  
Earnings per share (Unadj.) Rs5.117.9 28.5%  
Cash flow per share (Unadj.) Rs6.723.1 29.1%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.585.4 49.8%  
Shares outstanding (eoy) m158.231,023.74 15.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.0 85.4%   
Avg P/E ratio x25.025.7 97.1%  
P/CF ratio (eoy) x18.919.9 95.2%  
Price / Book Value ratio x3.05.4 55.6%  
Dividend payout %019.6 0.0%   
Avg Mkt Cap Rs m20,135470,664 4.3%   
No. of employees `0001.211.8 9.7%   
Total wages/salary Rs m70318,545 3.8%   
Avg. sales/employee Rs Th5,176.210,072.7 51.4%   
Avg. wages/employee Rs Th610.41,569.1 38.9%   
Avg. net profit/employee Rs Th699.61,547.7 45.2%   
INCOME DATA
Net Sales Rs m5,963119,049 5.0%  
Other income Rs m181,132 1.6%   
Total revenues Rs m5,981120,181 5.0%   
Gross profit Rs m1,43028,475 5.0%  
Depreciation Rs m2585,388 4.8%   
Interest Rs m-26911 -2.9%   
Profit before tax Rs m1,21623,308 5.2%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3425,644 6.1%   
Profit after tax Rs m80618,292 4.4%  
Gross profit margin %24.023.9 100.3%  
Effective tax rate %28.124.2 116.2%   
Net profit margin %13.515.4 88.0%  
BALANCE SHEET DATA
Current assets Rs m5,10282,005 6.2%   
Current liabilities Rs m2,38560,720 3.9%   
Net working cap to sales %45.617.9 254.8%  
Current ratio x2.11.4 158.4%  
Inventory Days Days15073 205.1%  
Debtors Days Days11398 115.2%  
Net fixed assets Rs m5,14883,703 6.2%   
Share capital Rs m1581,024 15.4%   
"Free" reserves Rs m6,55686,421 7.6%   
Net worth Rs m6,73287,445 7.7%   
Long term debt Rs m95225,551 3.7%   
Total assets Rs m10,388180,653 5.8%  
Interest coverage x-45.826.6 -172.2%   
Debt to equity ratio x0.10.3 48.4%  
Sales to assets ratio x0.60.7 87.1%   
Return on assets %7.510.6 70.6%  
Return on equity %12.020.9 57.2%  
Return on capital %14.622.0 66.4%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29842,683 12.4%   
Fx outflow Rs m1,77211,242 15.8%   
Net fx Rs m3,52531,441 11.2%   
CASH FLOW
From Operations Rs m1,2749,193 13.9%  
From Investments Rs m-1,204-9,737 12.4%  
From Financial Activity Rs m-196515 -38.1%  
Net Cashflow Rs m-126-29 435.5%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.3 3.6%  
FIIs % 9.6 5.9 162.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 11.0 82.7%  
Shareholders   42,599 44,069 96.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  PLETHICO PHARMA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Retail Inflation, Growth in India's Aviation Sector, and Top Cues in Focus Today(Pre-Open)

Share markets in India witnessed buying interest during closing hours yesterday and ended the day on a positive note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS